{"schema_version":"1","generated_at":"2026-11-04T04:10:04.713Z","data_as_of":null,"url":"https://www.findmykol.com/kol/zulfa-omer","json_url":"https://www.findmykol.com/kol/zulfa-omer/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"zulfa-omer","name":"Zulfa Omer","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Cincinnati","institution_url":"https://www.findmykol.com/institution/university-of-cincinnati","city":"Cincinnati","state":"OH","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1225559149","orcid":"0009-0001-4931-0961","openalex":"A5087330084"},"summary":"Zulfa Omer is an Oncology physician affiliated with University of Cincinnati. OpenAlex indexes 44 publications with 288 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":44,"cited_by_count":288,"h_index":8,"latest_activity_year":2026,"emerging":true,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT07014917","title":"Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Zulfa Omer","source_url":"https://clinicaltrials.gov/study/NCT07014917","trial_url":"https://www.findmykol.com/trial/NCT07014917"}],"source":"trials"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":5,"shown":3,"withheld":2,"rows":[{"payer":"AstraZeneca","program_year":2025,"amount_usd":379899.6,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1225559149"},{"payer":"AbbVie","program_year":2025,"amount_usd":7056,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1225559149"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":249.24,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1225559149"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1225559149","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Dermatology","share_pct":100,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":44,"shown":5,"withheld":39,"matched_by":"OpenAlex author record","recent":[{"title":"Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","year":2026,"journal":"Leukemia & lymphoma/Leukemia and lymphoma","source_url":"https://doi.org/10.1080/10428194.2026.2650679","status":"verified"},{"title":"POSTER: CLL-432: DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)00697-x","status":"verified"},{"title":"POSTER: CLL-427: Updated Efficacy and Safety Data From an Ongoing Phase 1a/b Trial of the Bruton's Tyrosine Kinase Degrader Bexobrutideg (NX-5948) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Across Lines of Therapy","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)00695-6","status":"verified"},{"title":"CLL-432: DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)02043-4","status":"verified"},{"title":"CLL-427: Updated Efficacy and Safety Data From an Ongoing Phase 1a/b Trial of the Bruton's Tyrosine Kinase Degrader Bexobrutideg (NX-5948) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Across Lines of Therapy","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)02041-0","status":"verified"}],"source":"works"},"contact":{"address_1":"3151 BELLEVUE AVE","city":"Cincinnati","state":"OH","zip":"452192370","phone":"513-584-7848","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1225559149","source":"identity"},"similar":[{"name":"Alberto Espay","slug":"alberto-espay","institution":"University of Cincinnati","specialty":"Neurology","url":"https://www.findmykol.com/kol/alberto-espay","json_url":"https://www.findmykol.com/kol/alberto-espay/profile.json"},{"name":"Davendra Sohal","slug":"davendra-sohal","institution":"University of Cincinnati","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/davendra-sohal","json_url":"https://www.findmykol.com/kol/davendra-sohal/profile.json"},{"name":"Punam Malik","slug":"punam-malik","institution":"University of Cincinnati","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/punam-malik","json_url":"https://www.findmykol.com/kol/punam-malik/profile.json"},{"name":"Eva Mistry","slug":"eva-mistry","institution":"University of Cincinnati","specialty":"Neurology","url":"https://www.findmykol.com/kol/eva-mistry","json_url":"https://www.findmykol.com/kol/eva-mistry/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":2,"publications":39}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2026-04-17","provider_certified":"2026-04-17","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}